Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders

A legfontosabb adatok

Ki végzi
National Human Genome Research Institute (NHGRI)
Hol
Bethesda (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
300 fő, tervezett
Kezdés
2002. febr. 6.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
1 nap – 100 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki nem vehet részt

  • There will be no exclusion based on race, gender, or ethnicity; however particular ethnic groups may be overrepresented due to the frequency of the diseases in a specific population (e.g., Ashkenazi Jews in infantile and adult GM2 and Roma "travelers" in juvenile GM1). The majority of juvenile subjects will have severely impaired decision-making and even informed assent in older children may not be possible. Children with Morquio B and sialidosis type 1 disease are not expected to be cognitively impaired. The children with Morquio B and sialidosis type 1 ages 7-11 years will be asked to give verbal assent and ages 12-17 years will be asked to give written assent to the protocol. Some subjects who have reached the age of 18 may need to have legally authorized representative (usually their parents) sign consent on their behalf

Egyéb feltételek

  • INCLUSION CRITERIA:; Any individual with GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis documented by enzyme deficiency or mutation analysis in a CLIA-approved laboratory will be eligible for the study

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • National Institutes of Health Clinical CenterBethesda, Egyesült ÁllamokContact: Jean M JohnstonRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Study description:

A teljes eredeti leírásKevesebb

This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated every 6 months for infantile onset disease, yearly for juvenile onset and approximately every two years for adult-onset disease as long as they are clinically stable to travel. Data will be evaluated serially for each patient, and cross-sectionally for patients of similar ages and genotypes. Genotype-phenotype correlations will be made where possible although these are rare disorders and the majority of the patients are compound heterozygotes.

Objectives:

To study the natural history and progression of neurodegeneration in individuals with glycosphingolipid storage disorders (GSL), GM1 and GM2 gangliosidosis, and glycoprotein (GP) disorders including sialidosis and galactosialidosis using clinical evaluation of patients and patient/parent surveys.

To develop sensitive tools for monitoring disease progression.

To identify biological markers in blood, cerebrospinal fluid, and urine that correlate with disease severity and progression and can be used as outcome measures for future clinical trials.

To further understand and characterize the mechanisms of neurodegeneration in GSL and GP storage disorders across the spectrum of disease beginning with ganglioside storage in fetal life.

Endpoints:

Exploring the natural history of Lysosomal Storage Diseases and Glycoprotein Disorders

Study Population:

Patients with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Accrual ceiling is 300 participants. No exclusions based on age, gender, demographic group, or demographic location. Patients included in our study are those that are seen at the NIH Clinical Center, subjects that have only sent in blood samples, as well as those who complete the questionnaire or provided head circumference measures.

A vizsgálat 2 csoportja

  • Glycoprotein Disorders
  • Lysosomal Storage Diseases

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. november 17.